CR Pharmaceutical completes Tasly Pharmaceuticals acquisition

China Resources Pharmaceutical Group (HKEX:3320) announced the completion of its proposed acquisition of a 28% interest in Tasly Pharmaceuticals Group Co., Ltd. The acquisition, executed through China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. ("CR Sanjiu"), was confirmed after China Securities Depository and Clearing Corporation Limited verified the transfer of 418,306,002 shares. With the transfer completed on March 27, 2025, Tasly Pharmaceuticals now becomes a non-wholly-owned subsidiary of China Resources Pharmaceutical Group. CR Sanjiu will proceed to settle the remaining consideration for the acquisition as per the share purchase agreement. This strategic move enhances China Resources Pharmaceutical Group’s portfolio and strengthens its position in the pharmaceutical market.